Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The Life Sciences Industry Report: Trends & Predictions 2025 is built for those who are serious about growth, innovation, and ...

Qu – which, according to Parsa, is the fruit of a collaboration between a global team of experienced AI scientists, ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...